Rochester, NY, March 01, 2025 — The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to introduce Carolyn Schultz-Walter as the Executive Director of Clinical Operations.
With over 25 years of global clinical operations experience spanning both sponsor and clinical research organization (CRO) settings, Carolyn brings a wealth of expertise in trial management, regulatory compliance, and project delivery. She has supported Phase I-IV studies in numerous therapeutic areas including Neuroscience and Neurology, and indications including Rare Disease and Pediatrics. Her distinguished career includes receiving several awards for excellence in clinical operations and project management, a testament to her exceptional leadership and commitment to clinical research.
“Carolyn’s experience, depth of knowledge, and strategic vision will be instrumental as we continue to strengthen and expand our ability to meet the needs of our HD clinical research community,” said Daniel Claassen, MD, Chief Executive Officer of HSG. “We are excited to have her on board and are confident that her expertise will help drive innovation and efficiency in our clinical trial operations.”
In her role, Carolyn will oversee the operational execution of global clinical trials, ensuring the highest standards in trial design, site management, and regulatory compliance. She will lead HSG’s clinical operations team, cultivating a collaborative and high-performing environment that enhances trial efficiency and delivers impactful results.
“I am excited to join HSG, work alongside such a passionate team, and work together to drive excellence,” said Carolyn Schultz-Walter. “The opportunity to contribute to the development of meaningful treatments to improve the quality of life for those living with Huntington’s disease is highly motivating, exciting, and fulfilling my passion to make a difference in patient care.”